EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

Delgado, Julio; Zienowicz, Malgorzata; van Hennik, Paula Boudewina; Moreau, Alexandre; Gisselbrecht, Christian; Enzmann, Harald; Pignatti, Francesco

Delgado, Julio; Zienowicz, Malgorzata; van Hennik, Paula Boudewina; Moreau, Alexandre; Gisselbrecht, Christian; Enzmann, Harald; Pignatti, Francesco.

Afiliação

Delgado J; Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.
Zienowicz M; Department of Hematology, Hospital Clinic, Barcelona, Spain.
van Hennik PB; Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.
Moreau A; Committe for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.
Gisselbrecht C; College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands.
Enzmann H; Committe for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.
Pignatti F; Agence Nationale de Securite du Medicament et des Produits de Sante, Saint-Denis, France.

Oncologist ; 26(11): 983-987, 2021 11.

Article em En | MEDLINE | ID: mdl-34213061

Assuntos

Mieloma Múltiplo; Neutropenia; Adulto; Anticorpos Monoclonais Humanizados; Dexametasona; Humanos; Mieloma Múltiplo/tratamento farmacológico; Talidomida/análogos & derivados

Palavras-chave

Dexamethasone; EMA â¢ Anti-CD38 antibody; Isatuximab; Multiple myeloma; Pomalidomide

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Neutropenia Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google